Drugs / NTX-1175
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05628740 Comparator | Feb → Oct 2022 | respiratory system disorder | Nocion Therapeutics | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NTX-1175 | “Part 1 will evaluate the safety, tolerability and PK of single doses of three dose levels of NTX-1175 drug substance administered by dry powder inhaler (NOC-110) compared to a...” NCT05628740 ↗ |
| Known as | NOC-100 | “NTX-1175 Administered Via Nebulizer (NOC-100) and Dry Powder Inhaler (NOC-110)” NCT05628740 ↗ |
| Known as | NOC-110 | “NTX-1175 Administered Via Nebulizer (NOC-100) and Dry Powder Inhaler (NOC-110)” NCT05628740 ↗ |